You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(02359.HK)擬認購私募基金500萬歐元份額
格隆匯 12-31 18:21

格隆匯12月31日丨藥明康德(02359.HK)公佈,2019年12月31日,公司全資子企業WuXi Fund I與JeitoS.L.P.(以下簡稱"投資基金"或"Jeito")簽署Subscription Agreement,約定由WuXi Fund I認繳500萬歐元的A2類投資基金份額,約佔已募集投資基金份額的2.5%。截至公告日,WuXi Fund I尚未實繳出資,後續WuXi Fund I將以自有資金根據認購協議及管理公司的出資要求履行出資義務。

JeitoS.L.P.為一家依據法國法律成立的有限合夥企業,投資基金專注於投資生物醫藥領域早期和成長期的企業。預計募集總額不超過5億歐元,WuXi Fund I此次認繳500萬歐元后,投資基金已募集200,000,200歐元。

Jeito的投資將主要針對生物醫藥領域早期和成長期企業,公司認為其管理團隊在歐洲投資市場所積累的豐富經驗和廣泛聯繫使其有能力和機會識別該領域的高質量創新成果,並通過投資幫助此類早期和成長期企業獲得資金以加速其創新成果的商業化。公司以較低比例投資Jeito作為其有限合夥人,一方面有望使公司在投資風險可控的前提下,獲得風險投資相關的財務收益;另一方面,Jeito投資所針對的生物醫藥領域早期和成長期企業是公司重要的潛在客户羣體,該項投資還可以增進公司對歐洲生物醫藥領域發展最新動態的深入瞭解,為公司在歐洲拓展市場提供前瞻性指引。公司在保證日常經營發展所需資金的前提下,以自有資金參與認繳投資基金份額,此次投資不會對公司財務狀況和經營成果產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account